Trial updateRetina
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Recruiting. Phase 3. Registered enrolment: 975. Regeneron Pharmaceuticals
Why it matters
Track this study through NCT06541704. No results are posted in this registry record.
The study at a glance
- Registry status
- Recruiting
- Phase
- Phase 3
- Registered enrolment
- 975
- Results posted
- No
- Sponsor
- Regeneron Pharmaceuticals
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.
References (1)
Source date: 18 Sept 2026 · United States · Australia · Austria · Canada · France · Germany · Hungary · Italy · Poland · Spain · United Kingdom